Saturday 17 October 2026
Export IMDX’s income statement to Excel — free account
Insight Molecular Diagnostics Inc.
IMDX Healthcare Diagnostics & Research
Insight Molecular Diagnostics Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.1 million, up 115.6% from fiscal 2024. In the quarter to June 2026, revenue fell 53.9%, EPS fell 3.33% and free cash flow fell 54.0%, each against the same quarter a year earlier. Revenue growth for three consecutive years; insiders bought in the last twelve months.
3.01
0.05
−1.63%
Follow IMDX
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
129.84 | 58.09 | 56.37 | 24.16 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(23.39) | (14.82) | (41.22) | (22.99) | |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
119.31 | 44.12 | 53.75 | 20.22 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(7.36) | (3.58) | (9.82) | (4.05) | |
EV/FCF |
(6.43) | (3.13) | (8.59) | (3.72) | |
Quick Ratio |
1.82 | 2.42 | 1.11 | 2.57 | |
Current Ratio |
2.00 | 2.54 | 1.27 | 2.79 | |
Net Debt/EBITDA |
1.64 | 7.65 | 0.46 | 1.86 | |
Debt/Assets |
3.11% | 0.00% | 6.56% | 0.00% | |
Debt/Equity |
(0.04) | 0.00 | (0.05) | 0.00 | |
Asset Turnover |
0.04 | 0.04 | 0.13 | 0.08 | |
Operating CF/Net income |
0.82 | 1.78 | 0.24 | 0.43 | |
Capex/Depreciation |
(1.17) | (0.97) | (2.63) | (1.80) | |
Interest Coverage |
(570.10) | (191.87) | (901.35) | (380.97) | |
Research and Development Expense of Revenue |
1,876.99% | 15,478.13% | 511.76% | 1,491.54% | |
Selling, General and Administrative Expense of Revenue |
2,003.77% | 16,853.13% | 405.36% | 1,511.92% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.33 | |
Share Based Compensation of Revenue |
276.57% | 1,921.88% | 63.30% | 200.38% | |
Graham Net Nets |
(0.14) | (0.18) | (0.18) | (0.30) | |
Graham Number |
4.41 | 3.21 | 6.13 | 4.28 | |
Earnings Yield |
(25.25%) | (45.12%) | (21.60%) | (85.24%) | |
Free Cash Flow Yield |
(14.30%) | (24.27%) | (11.10%) | (22.48%) | |
Revenue per Share |
0.01 | 0.00 | 0.04 | 0.01 | |
Operating CF per Share |
(0.25) | (0.22) | (0.18) | (0.14) | |
Capex per Share |
(0.02) | (0.02) | (0.05) | (0.03) | |
Free Cash Flow per Share |
(0.27) | (0.24) | (0.23) | (0.18) | |
Cash per Share |
0.50 | 0.84 | 0.40 | 0.61 | |
Shareholders Equity per Share |
(0.58) | (0.31) | (1.03) | (0.29) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(0.58) | (0.31) | (1.03) | (0.29) | |
Free Cash Flow |
(10.05) | (8.25) | (7.02) | (5.68) | |
Working Capital |
10.26 | 18.51 | 3.23 | 13.73 | |
Capital Expenditures |
(0.78) | (0.61) | (1.48) | (1.05) | |
Net Current Asset Value |
(30.20) | (20.60) | (41.91) | (31.74) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
3.26 | 19.16 | 1.30 | 4.04 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
0.35 | 1.85 | 1.37 | 0.23 | |
Average Payables |
1.57 | 1.95 | 2.09 | 0.96 | |
Average Inventory |
0.45 | 0.42 | 0.43 | 0.35 | |
Average Assets |
39.98 | 50.39 | 30.42 | 57.08 | |
Average Common Equity |
(10.10) | (0.24) | (21.87) | 0.26 |
Columns are period end dates